Spots Global Cancer Trial Database for A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors
Official Title: A Phase 1, Open Label Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2171 and Selected Chemotherapy Regimens When Given in Combination to Patients With Advanced Solid Tumors
Study ID: NCT00502567
Conditions
Study Description
Brief Summary: A multicentre, 2-part study to assess the safety and tolerability of once daily oral doses of AZD2171 when administered with various anticancer regimens (part A) and to confirm the tolerability of its combination with FOLFOX (part B).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Ann Arbor, Michigan, United States
Research Site, Detroit, Michigan, United States
Research Site, Nashville, Tennessee, United States
Contact Details
Name: Jane Robertson
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Name: Bijoyesh Mookerjee, MD
Affiliation: AstraZeneca
Role: STUDY_CHAIR
Name: Patricia LoRusso, DO
Affiliation: Wayne State University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
